Skip Navigation

Cardiovascular Research 1998 37(3):564-566; doi:10.1016/S0008-6363(97)00303-9
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Levi, M.
Right arrow Articles by R. Büller, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levi, M.
Right arrow Articles by R. Büller, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Weight watching in cardiology: low molecular weight heparin for acute coronary syndromes

Marcel Levia,*, Ron J.G. Petersb and Harry R. Büllera

aCenter for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
bDept. of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

* Corresponding author: Tel.: +31 (20) 5669111; fax: +31 (20) 6968833; E-mail m.m.levi@amc.uva.nl

The first 10% of the full text of this article appears below.

Heparin is available for clinical use since the 1950's and has over the last years firmly established its role as the anticoagulant agent of choice in the prevention and treatment of venous thromboembolism as well as in the management of acute coronary syndromes [1]. Heparin anticoagulation, however, has limitations, partly due to the unpredictable bioavailability of the compound and its large inter- and intraindividual biological effect, requiring continuous intravenous infusion, frequent monitoring of anticoagulation and dose adjustments. Furthermore, the present anticoagulant treatment of patients in a number of clinical situations, such as unstable angina, is still associated with unsatisfactory efficacy and safety in a substantial number of patients.

Recently, low molecular weight heparins (LMWH's), . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
T. O. Cheng
Low-Molecular-Weight Heparin for Unstable Angina
Chest, December 1, 1999; 116(6): 1833 - 1833.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
T. O. Cheng
Weight Watching in Heparin
Arch Intern Med, May 24, 1999; 159(10): 1142 - 1142.
[Full Text] [PDF]